European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

EAU17: Prostate Cancer Prevention Group tackles limits of active surveillance

Fri, 24 Mar 2017
Enlarge image

The question of which of prostate cancer (PCa) patients are suitable for active surveillance (AS) remains a complex issue, and experts yesterday cautioned that doctors should exercise due restraint to avoid over-treatment.

The special session organized by the Prostate Cancer Prevention Group looked into the low-risk PCa and identifying patients qualified for active surveillance, such as genetic factors, dietary and lifestyle, the role of miRNA, tissue, blood and urine–based biomarkers, role of imaging, and management of low-risk disease, among others. The full-day session also presented update lectures and discussions of the three major studies on AS (ProtecT, ERSPC and PLCO).

“There is a general acceptance that there is overtreatment and that the question of screening has exacerbated that,” said Prof. Jack Cuzick (GB) who chaired the meeting with Profs. Manfred Wirth (DE) and Arnulf Stenzl (DE).

Prof. Freddie Hamdy (GB) gave updates on the ProtecT study and said the risk of death from prostate cancer over an average of 10 years is very low (1%) and that most PSA-detected clinically localized prostate cancers grow slowly.

“Surgery and radiotherapy reduce the risk of cancer progression and spread, but cause bothersome urinary, sexual and bowel symptoms,” added Hamdy. He also noted that patients who stayed on active monitoring avoid treatment side-effects. “But there is an increased risk of cancer progression and spread, and some symptoms increase gradually over time,” said Hamdy.

Share this article

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer